HC Wainwright reaffirmed their buy rating on shares of Werewolf Therapeutics (NASDAQ:HOWL - Free Report) in a research note issued to investors on Tuesday morning,Benzinga reports. They currently have a $15.00 price target on the stock.
Werewolf Therapeutics Price Performance
Shares of NASDAQ HOWL traded down $0.04 during midday trading on Tuesday, hitting $1.68. The company had a trading volume of 466,606 shares, compared to its average volume of 378,989. The firm has a market capitalization of $74.64 million, a price-to-earnings ratio of -1.12 and a beta of 0.41. Werewolf Therapeutics has a twelve month low of $1.59 and a twelve month high of $8.19. The business has a 50-day simple moving average of $2.26 and a two-hundred day simple moving average of $2.81. The company has a quick ratio of 10.10, a current ratio of 10.10 and a debt-to-equity ratio of 0.29.
Institutional Trading of Werewolf Therapeutics
Institutional investors have recently bought and sold shares of the company. Millennium Management LLC boosted its position in shares of Werewolf Therapeutics by 96.4% in the 2nd quarter. Millennium Management LLC now owns 1,110,298 shares of the company's stock worth $2,709,000 after buying an additional 544,881 shares in the last quarter. Janus Henderson Group PLC purchased a new position in shares of Werewolf Therapeutics during the 1st quarter worth approximately $10,922,000. Acadian Asset Management LLC raised its position in shares of Werewolf Therapeutics by 119.8% during the 1st quarter. Acadian Asset Management LLC now owns 172,883 shares of the company's stock worth $1,119,000 after purchasing an additional 94,212 shares during the last quarter. Vanguard Group Inc. lifted its stake in Werewolf Therapeutics by 26.8% in the 1st quarter. Vanguard Group Inc. now owns 1,107,347 shares of the company's stock valued at $7,176,000 after buying an additional 233,909 shares in the last quarter. Finally, Renaissance Technologies LLC grew its holdings in Werewolf Therapeutics by 103.1% during the 2nd quarter. Renaissance Technologies LLC now owns 171,000 shares of the company's stock valued at $417,000 after buying an additional 86,800 shares during the last quarter. 64.84% of the stock is currently owned by hedge funds and other institutional investors.
Werewolf Therapeutics Company Profile
(
Get Free Report)
Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.
Featured Stories
Before you consider Werewolf Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Werewolf Therapeutics wasn't on the list.
While Werewolf Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
